Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mental Health | 6 | 2023 | 415 | 3.230 |
Why?
|
| Psychiatry | 6 | 2023 | 307 | 2.180 |
Why?
|
| Depressive Disorder, Major | 9 | 2021 | 441 | 2.080 |
Why?
|
| Brain | 15 | 2024 | 4113 | 2.050 |
Why?
|
| Pharmacogenetics | 7 | 2020 | 260 | 1.820 |
Why?
|
| Antidepressive Agents | 9 | 2021 | 332 | 1.540 |
Why?
|
| Diplomacy | 4 | 2023 | 11 | 1.340 |
Why?
|
| Inventions | 2 | 2020 | 37 | 1.230 |
Why?
|
| Dementia | 3 | 2023 | 453 | 1.120 |
Why?
|
| Alzheimer Disease | 3 | 2023 | 855 | 1.060 |
Why?
|
| Yoga | 2 | 2017 | 78 | 1.030 |
Why?
|
| Geriatric Psychiatry | 4 | 2023 | 17 | 1.010 |
Why?
|
| City Planning | 1 | 2023 | 1 | 0.960 |
Why?
|
| Literacy | 1 | 2023 | 10 | 0.950 |
Why?
|
| Neurosciences | 2 | 2021 | 53 | 0.940 |
Why?
|
| Pharmacogenomic Testing | 2 | 2021 | 46 | 0.940 |
Why?
|
| Neural Pathways | 2 | 2016 | 298 | 0.930 |
Why?
|
| Technology | 2 | 2020 | 96 | 0.870 |
Why?
|
| Resilience, Psychological | 2 | 2020 | 64 | 0.850 |
Why?
|
| Mental Disorders | 5 | 2023 | 862 | 0.830 |
Why?
|
| Depression | 4 | 2019 | 1715 | 0.810 |
Why?
|
| Capital Financing | 1 | 2021 | 13 | 0.810 |
Why?
|
| Interdisciplinary Research | 1 | 2021 | 8 | 0.810 |
Why?
|
| Investments | 1 | 2020 | 13 | 0.770 |
Why?
|
| Work | 1 | 2020 | 24 | 0.760 |
Why?
|
| Efficiency | 1 | 2020 | 99 | 0.730 |
Why?
|
| Aerospace Medicine | 1 | 2020 | 51 | 0.730 |
Why?
|
| Weightlessness | 1 | 2020 | 72 | 0.730 |
Why?
|
| Entrepreneurship | 2 | 2020 | 8 | 0.730 |
Why?
|
| Social Support | 1 | 2023 | 560 | 0.720 |
Why?
|
| Science | 2 | 2020 | 35 | 0.720 |
Why?
|
| Ecosystem | 1 | 2020 | 111 | 0.710 |
Why?
|
| Public Health | 1 | 2022 | 299 | 0.710 |
Why?
|
| Decision Support Techniques | 3 | 2020 | 622 | 0.700 |
Why?
|
| Organizational Innovation | 1 | 2019 | 68 | 0.670 |
Why?
|
| Space Flight | 1 | 2020 | 158 | 0.650 |
Why?
|
| Aging | 3 | 2022 | 1582 | 0.650 |
Why?
|
| Vilazodone Hydrochloride | 1 | 2017 | 2 | 0.610 |
Why?
|
| Paroxetine | 1 | 2017 | 34 | 0.600 |
Why?
|
| Health Promotion | 1 | 2021 | 502 | 0.580 |
Why?
|
| Plaque, Amyloid | 1 | 2017 | 65 | 0.570 |
Why?
|
| Interdisciplinary Studies | 1 | 2016 | 7 | 0.570 |
Why?
|
| Transcription Factor AP-1 | 1 | 2017 | 246 | 0.550 |
Why?
|
| Late Onset Disorders | 1 | 2015 | 1 | 0.550 |
Why?
|
| Citalopram | 1 | 2015 | 36 | 0.540 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 46 | 0.540 |
Why?
|
| Creativity | 1 | 2015 | 13 | 0.530 |
Why?
|
| Rest | 1 | 2015 | 71 | 0.530 |
Why?
|
| Mood Disorders | 2 | 2021 | 163 | 0.530 |
Why?
|
| Health Personnel | 1 | 2020 | 625 | 0.520 |
Why?
|
| Amyloid beta-Peptides | 1 | 2017 | 246 | 0.510 |
Why?
|
| Methylphenidate | 1 | 2015 | 103 | 0.510 |
Why?
|
| tau Proteins | 1 | 2017 | 216 | 0.510 |
Why?
|
| Cognitive Dysfunction | 2 | 2017 | 333 | 0.510 |
Why?
|
| Forecasting | 1 | 2018 | 694 | 0.510 |
Why?
|
| Chemokines | 1 | 2016 | 314 | 0.490 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 860 | 0.480 |
Why?
|
| Complementary Therapies | 1 | 2015 | 126 | 0.470 |
Why?
|
| Temporal Lobe | 1 | 2015 | 192 | 0.470 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2014 | 200 | 0.470 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 118 | 0.460 |
Why?
|
| Pilot Projects | 5 | 2017 | 2803 | 0.430 |
Why?
|
| Memory | 1 | 2016 | 429 | 0.420 |
Why?
|
| Humans | 45 | 2024 | 261506 | 0.420 |
Why?
|
| Global Health | 4 | 2023 | 657 | 0.410 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 461 | 0.400 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 521 | 0.380 |
Why?
|
| Students, Medical | 1 | 2015 | 399 | 0.360 |
Why?
|
| Quality of Life | 1 | 2023 | 4532 | 0.350 |
Why?
|
| Cognition Disorders | 1 | 2015 | 786 | 0.340 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2017 | 901 | 0.340 |
Why?
|
| Bipolar Disorder | 2 | 2022 | 376 | 0.320 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 671 | 0.310 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 2173 | 0.310 |
Why?
|
| Cytokines | 1 | 2017 | 2809 | 0.310 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 2 | 2020 | 92 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 2594 | 0.290 |
Why?
|
| Mental Health Services | 2 | 2021 | 227 | 0.280 |
Why?
|
| Functional Neuroimaging | 2 | 2016 | 38 | 0.270 |
Why?
|
| Clinical Competence | 1 | 2014 | 1270 | 0.270 |
Why?
|
| Precision Medicine | 3 | 2019 | 1154 | 0.270 |
Why?
|
| Head | 2 | 2024 | 249 | 0.260 |
Why?
|
| Internship and Residency | 1 | 2015 | 1375 | 0.240 |
Why?
|
| Australia | 4 | 2022 | 225 | 0.230 |
Why?
|
| Aged | 12 | 2023 | 70117 | 0.230 |
Why?
|
| Life Change Events | 1 | 2023 | 83 | 0.230 |
Why?
|
| Teaching | 2 | 2015 | 243 | 0.220 |
Why?
|
| Learning | 2 | 2017 | 403 | 0.220 |
Why?
|
| Frontotemporal Dementia | 1 | 2022 | 40 | 0.210 |
Why?
|
| Antipsychotic Agents | 2 | 2017 | 414 | 0.210 |
Why?
|
| China | 1 | 2024 | 606 | 0.210 |
Why?
|
| International Cooperation | 2 | 2023 | 323 | 0.200 |
Why?
|
| Biomedical Research | 2 | 2021 | 806 | 0.190 |
Why?
|
| Healthy Aging | 1 | 2020 | 9 | 0.190 |
Why?
|
| Employment | 1 | 2020 | 129 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 226 | 0.180 |
Why?
|
| Geriatrics | 1 | 2020 | 98 | 0.170 |
Why?
|
| Program Development | 1 | 2020 | 261 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2021 | 280 | 0.170 |
Why?
|
| Neurology | 1 | 2020 | 113 | 0.170 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 160 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 4314 | 0.170 |
Why?
|
| Psychotropic Drugs | 1 | 2020 | 133 | 0.170 |
Why?
|
| Apathy | 1 | 2017 | 19 | 0.150 |
Why?
|
| Brain Diseases | 1 | 2020 | 403 | 0.150 |
Why?
|
| Lithium Compounds | 1 | 2016 | 15 | 0.140 |
Why?
|
| California | 1 | 2017 | 208 | 0.140 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 194 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1225 | 0.140 |
Why?
|
| Neuropsychological Tests | 2 | 2022 | 1178 | 0.140 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2015 | 22 | 0.140 |
Why?
|
| Administrative Personnel | 1 | 2015 | 35 | 0.140 |
Why?
|
| Executive Function | 1 | 2017 | 160 | 0.130 |
Why?
|
| Education, Continuing | 1 | 2015 | 34 | 0.130 |
Why?
|
| Occipital Lobe | 1 | 2015 | 48 | 0.130 |
Why?
|
| Affect | 1 | 2017 | 288 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 289 | 0.120 |
Why?
|
| Cognition | 1 | 2020 | 968 | 0.120 |
Why?
|
| United Kingdom | 1 | 2014 | 257 | 0.120 |
Why?
|
| Patient Participation | 1 | 2017 | 446 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2017 | 557 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 849 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 2315 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2017 | 667 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2014 | 233 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 29902 | 0.110 |
Why?
|
| Schizophrenia | 1 | 2016 | 369 | 0.110 |
Why?
|
| Nitriles | 1 | 2017 | 906 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 669 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2022 | 7702 | 0.100 |
Why?
|
| Leadership | 1 | 2014 | 254 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2017 | 2588 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 1301 | 0.100 |
Why?
|
| Male | 7 | 2017 | 123000 | 0.100 |
Why?
|
| Middle Aged | 6 | 2017 | 86204 | 0.100 |
Why?
|
| Female | 8 | 2019 | 141928 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 2403 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 918 | 0.090 |
Why?
|
| Telemedicine | 1 | 2015 | 471 | 0.090 |
Why?
|
| United States | 2 | 2023 | 15433 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 2265 | 0.070 |
Why?
|
| Physicians | 1 | 2015 | 882 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 4320 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 4053 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 6100 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 5539 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5159 | 0.060 |
Why?
|
| Young Adult | 1 | 2023 | 21445 | 0.060 |
Why?
|
| Delusions | 1 | 2023 | 21 | 0.060 |
Why?
|
| New South Wales | 1 | 2022 | 8 | 0.050 |
Why?
|
| Government | 1 | 2022 | 16 | 0.050 |
Why?
|
| Ontario | 1 | 2022 | 98 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 14889 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 5687 | 0.050 |
Why?
|
| Organizations | 1 | 2020 | 23 | 0.050 |
Why?
|
| Sleep | 1 | 2023 | 413 | 0.050 |
Why?
|
| Models, Organizational | 1 | 2020 | 76 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2020 | 43 | 0.040 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2020 | 51 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 429 | 0.040 |
Why?
|
| Models, Psychological | 1 | 2020 | 170 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2020 | 176 | 0.040 |
Why?
|
| Adult | 2 | 2023 | 77950 | 0.040 |
Why?
|
| Psychotherapy | 1 | 2020 | 247 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1021 | 0.040 |
Why?
|
| Epigenomics | 1 | 2019 | 266 | 0.040 |
Why?
|
| Aripiprazole | 1 | 2016 | 22 | 0.040 |
Why?
|
| Organization and Administration | 1 | 2015 | 8 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 142 | 0.030 |
Why?
|
| Bupropion | 1 | 2016 | 76 | 0.030 |
Why?
|
| Environment | 1 | 2016 | 190 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2015 | 140 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1559 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 5047 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 1287 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2019 | 2669 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2019 | 2947 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 6295 | 0.020 |
Why?
|
| Child | 1 | 2020 | 29154 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 17523 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 32848 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 59536 | 0.010 |
Why?
|